Insomnia Disorder (ID) is the second-most prevalent mental disorder[@R1] with prevalence estimates ranging from 10% (adults) to 22% (elderly)[@R2],[@R3], and is characterized by lasting problems falling asleep or waking up in the night or early morning, with subjective repercussions for daytime functioning. It is the primary risk factor for depression[@R4] and contributes to the risks of cardiovascular disease[@R5]--[@R9], type 2 diabetes[@R10] and obesity[@R11]. Heritability estimates of 38% (males) and 59% (females)[@R12] suggest a substantial role for genetic factors. In contrast to presumed neurobiological mechanisms involved in most mental disorders, it has been suggested that insomnia merely involves reversible maladaptive learning of sleep-related cognitions and behaviors[@R13],[@R14]. Indeed, interventions that address these are at least partly effective in about two-thirds of cases[@R15], but ameliorate complaints only by about 50%[@R16], often resulting in a persistent course[@R17]. Family and twin studies suggest the involvement of genetic factors in the etiology of insomnia[@R18]--[@R21]. However, few, and mainly underpowered (*n* \< 5,000) linkage and association studies of insomnia-related phenotypes have been conducted, and recent larger studies used non-validated proxy measures for ID[@R22]--[@R24]. For example, the habitual duration or the timing of sleep[@R25],[@R26] do not discriminate reliably between cases and controls of ID[@R27], and therefore genes found for these phenotypes are not indicative of biological mechanisms of insomnia. The most recent GWAS for sleep disturbance traits reported several novel loci[@R24]. However, this study did not provide information on the predictive accuracy of the included traits for ID, making it difficult to interpret their findings in terms of clinical relevance. In addition, their top finding (*MEIS1*) is a known risk factor for Restless Legs Syndrome (RLS), and it is still unclear whether the shared associations in this gene reflect causality, partial mediation or pleiotropy[@R24].

Here we report a GWAS using the UK Biobank sample[@R28] (see [URLs](#FN1){ref-type="fn"}) including 113,006 individuals (mean age 56.92, *sd* = 7.94) to identify genetic risk factors for insomnia complaints ([Online Methods](#S13){ref-type="sec"}, [Supplementary Table 1](#SD1){ref-type="supplementary-material"}). The discriminative value of insomnia complaints for identifying ID cases versus controls was validated in an independent cohort (*n* = 1,918). In addition, we report extensively on the possible mechanisms of action explaining the shared genetic signal in *MEIS1* for insomnia complaints and RLS.

Results {#S1}
=======

Insomnia complaints is predictive of Insomnia Disorder {#S2}
------------------------------------------------------

ID was assessed by using a single question on trouble falling asleep and waking up in the middle of the night ([Supplementary Note, Supplementary Fig. 1](#SD1){ref-type="supplementary-material"}). Individuals that answered 'usually' were scored as cases and individuals reporting 'never/rarely' or 'sometimes' were scored as controls. We note that this operationalization differs from[@R24] where the same question in the UK Biobank sample was used but where cases were defined as scoring 'usually' and controls as scoring 'never/rarely' ([Supplementary Note](#SD1){ref-type="supplementary-material"}). We validated the predictive utility of this question for ID in an independent sample of 1,918 participants (845 insomniacs and 1,073 controls) of the Netherlands Sleep Registry[@R29] (NSR, see [URLs](#FN1){ref-type="fn"}) ([Supplementary Note](#SD1){ref-type="supplementary-material"}). The equivalent of the UK Biobank question (using our response category cut-off) in the NSR had a sensitivity of 98%, and a specificity of 96% in discriminating questionnaire-defined insomnia ID cases from non-affected controls (χ^2^ = 1356.45, *P* \< 0.0001), or discriminating ID cases from cases with exclusively RLS (sensitivity 0.96, specificity 0.97, χ^2^ = 639.06, *P* \< 0.0001; [Supplementary Note, Supplementary Table 2](#SD1){ref-type="supplementary-material"}). It did not discriminate RLS from controls well, with a sensitivity of only 0.43, and a specificity of 0.74 (χ^2^ = 1.28, *P* = 0.26; [Supplementary Fig. 1 and 2, Supplementary Table 2](#SD1){ref-type="supplementary-material"}), nor any cases versus controls of 19 possibly related disease categories ([Supplementary Note, Supplementary Fig. 3](#SD1){ref-type="supplementary-material"}). Further strong support for the validity of the UK Biobank insomnia phenotype was provided by an accuracy of correct classification of 91% of clinical ID in NSR participants diagnosed by a structured interview ([Supplementary Note](#SD1){ref-type="supplementary-material"}). Moreover, sleep and mood characteristics of individuals who reported difficulties falling and staying asleep closely resembled the corresponding profile of NSR participants with ID, but not the profile of those with RLS ([Supplementary Note, Supplementary Fig. 4](#SD1){ref-type="supplementary-material"}). These findings show that the UK Biobank insomnia phenotype is predictive of ID, with little confounding by comorbidity. We will refer to this classification as \'insomnia complaints\'.

Implicated genes and functional mechanisms {#S3}
------------------------------------------

Prevalence of insomnia complaints was 29% in the UK Biobank sample ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}, and further descriptives in [Supplementary Table 3](#SD1){ref-type="supplementary-material"}), in keeping with previous estimates for people with advanced age in the UK[@R30] and elsewhere[@R31],[@R32]. Females (33%) had a higher prevalence than males (24%). The sex odds ratio of 1.37 matches the previously published meta-analytic estimate of 1.41[@R2]. GWAS was performed on all individuals of European descent, and standard quality-control procedures included correction for population stratification and filtering on minor allele frequency and imputation quality ([Online Methods](#S13){ref-type="sec"}). The GWAS included 12,444,916 SNPs. The pooled-sex analysis identified two genome-wide significant loci ([Fig. 1a](#F1){ref-type="fig"}; [Table 1](#T1){ref-type="table"}), implicating two genes: *MEIS1* on chromosome 2 and *SCFD2* on chromosome 4 ([Supplementary Fig. 5a/b](#SD1){ref-type="supplementary-material"}). Sex-specific analyses revealed *MEIS1* for females as well, including the same significant SNPs found in the pooled-sex analysis, and an additional locus for males, *WDR27* on chromosome 6 ([Fig. 1b/c](#F1){ref-type="fig"}; [Table 1](#T1){ref-type="table"}; [Supplementary Fig. 5c/d](#SD1){ref-type="supplementary-material"}). Both *MEIS1* and *WDR27* have been identified by the recent GWAS for sleep disturbance[@R24] traits using the UK Biobank data as well, using a slightly different insomnia phenotype ([Supplementary Note, Supplementary Figs. 6 and 7](#SD1){ref-type="supplementary-material"}). Our top SNPs in both genes were the same as in this study with similar association signals (*MEIS1*: rs113851554, *P*=9.11×10^-19^; *WDR27*: rs13192566, *P*=3.17×10^-8^).

Possible functional mechanisms of the identified SNPs and the SNPs in high LD (r^2^ \> 0.6) are reported in the [Supplementary Note](#SD1){ref-type="supplementary-material"} and [Supplementary Table 4](#SD4){ref-type="supplementary-material"}. The majority of genome-wide significant SNPs were intronic and unlikely to be deleterious, or part of a regulatory element. However, the SNPs in the locus at chromosome 6 were associated with increased expression of two neighboring genes in blood cells (*PHF10*, lowest *P* = 3.65 × 10^-13^; *C6orf120*, lowest *P* = 3.81 × 10^-13^). One SNP (rs113851554) in the *MEIS1* locus showed evidence (*P* = 1.08 × 10^-6^, FDR \< 0.05) to act as a cis-methylation quantitative trait locus (meQTL). Credible set analysis ([Online Methods](#S13){ref-type="sec"}) of the SNPs in the *MEIS1* locus identified 2 variants (rs113851554 and rs182588061) within the 99% confidence set that are plausibly the causal variants ([Supplementary Table 5](#SD1){ref-type="supplementary-material"}). When incorporating functional annotation, rs113851554 accounted for the full posterior probability, suggesting that the most strongly associated SNP in the *MEIS1* locus is also the most likely causal SNP.

SNP heritability {#S4}
----------------

SNP-based heritability was estimated at 0.09 (SE=0.0082) by LD score regression[@R33] (LDSC) and at 0.11 (SE = 0.0093) by BOLT-REML[@R34] (BR) analysis. The sex difference was small with estimates at 0.12 (SE=0.018; LDSC) and 0.11 (SE = 0.02; BR) in males, versus 0.08 (SE = 0.014; LDSC) and 0.09 (SE = 0.02; BR) in females. The quantile-quantile (Q-Q) plots of all SNPs exhibited only mild inflation (λ~ALL~ = 1.11; λ~M~ = 1.06; λ~F~ = 1.05; [Supplementary Fig. 8](#SD1){ref-type="supplementary-material"}) as is expected for a polygenic trait using the current sample size. The intercepts estimated by LDSC of 1.00, 0.99, and 1.00 for sex-combined, males and females respectively, suggested that this mild inflation was unlikely to be due to population stratification.

Gene-based results {#S5}
------------------

A genome-wide gene-association study (GWGAS) as implemented in MAGMA[@R35] ([Online Methods](#S13){ref-type="sec"}) on all individuals identified three genes: *MEIS1* (also implicated by the GWAS), *DCBLD1* and *MED27*. Sex-specific GWGAS identified two additional genes (*HHEX* and *RHCG*) for males, and two additional genes (*IPO7* and *TSNARE1*) for females ([Fig. 1d/e/f](#F1){ref-type="fig"}, [Table 2](#T2){ref-type="table"}, [Supplementary Table 6](#SD5){ref-type="supplementary-material"}). Some of these genes have been associated before with other phenotypes such as diabetes and schizophrenia ([Supplementary Table 7; Supplementary Note section 3.1](#SD1){ref-type="supplementary-material"}). The top gene *MEIS1* encodes a homeobox protein that acts as transcriptional regulator and activator, and it is thought to be important for normal development[@R36]. The highest expression levels are found in the female internal reproductive organs, but it is expressed in many other tissues as well, including the brain[@R37]. *HHEX* and *MED27* are involved in the regulation of transcription as well. *TSNARE1* and *SCFD2* (implicated in the GWAS) play a role exocytosis ([Supplementary Note, Supplementary Tables 8](#SD1){ref-type="supplementary-material"}, [9](#SD6){ref-type="supplementary-material"}, [Supplementary Figs. 9-12](#SD1){ref-type="supplementary-material"}).

Joint analysis with independent sample {#S6}
--------------------------------------

To examine the robustness of the 3 loci and 7 genes that reached genome-wide significance in the primary analyses, we tested their associations with a well-defined insomnia phenotype in the deCODE sample of *n*=7,565 ([Online Methods](#S13){ref-type="sec"}, [Supplementary Note, Supplementary Tables 10-12](#SD1){ref-type="supplementary-material"}), and meta-analyzed these results with the UK Biobank association results, while adhering to the GWAS significance threshold of 5 × 10^-8^ ([Online Methods](#S13){ref-type="sec"}, [Supplementary Tables 13 and 14](#SD1){ref-type="supplementary-material"}). The probability to replicate significant SNPs in the deCODE sample was low due to the difference in sample size ([Supplementary Note section 4 and Supplementary Table 15](#SD1){ref-type="supplementary-material"}), whereas a meta-analysis takes into account standard errors (i.e. sample size) of the observed effects, and allows to evaluate whether discovery *P* values increase (suggesting no replication) or decrease (supporting a similar effect in the added sample)[@R38]. Effects of 11 out of 12 SNPs from the full (both sexes combined) GWAS and all five SNPs from the female GWAS were sign concordant while the three SNPs from the GWAS in males were not. Only SNPs in the *MEIS1* locus showed a stronger association signal (six SNPs in the full, and two SNPs in the females GWAS). Six out of seven genes detected in the GWGAS were significant at the genome-wide threshold of 5 × 10^-8^ in the meta-analysis. The signal for *MEIS1*, as well as for the four genes associated in the sex-specific analyses, showed a stronger association, and remained below the genome-wide gene-based threshold of association.

The role of *MEIS1* in insomnia complaints and RLS {#S7}
--------------------------------------------------

Most strongly associated with insomnia complaints was *MEIS1*. Winkelmann and colleagues[@R39],[@R40] previously reported an association of multiple SNPs in *MEIS1* with RLS, and two of our top SNPs have been associated before with clinically diagnosed RLS patients in a sequencing[@R41] and gene expression study[@R42] of *MEIS1*. RLS is a prevalent disorder characterized by the urge to move the legs, a symptom which has been suggested to involve deficiencies in the dopaminergic system, while arousals during sleep, which is present in some RLS patients, is related to the glutamate/GABA balance[@R43]. The latter has also been implicated in hyperarousal in insomnia[@R44]. RLS and insomnia have some form of agitation or restlessness in common: expressed primarily in the cognitive domain in insomnia, and in the sensorimotor domain in RLS. Given the possible phenotypic overlap and reported genetic associations in *MEIS1* for RLS, we investigated the mechanisms of action that can explain the shared signal in *MEIS1* for insomnia complaints and RLS.

First, we investigated whether the observed associations of *MEIS1* with insomnia complaints and RLS are independent. At least two signals in *MEIS1* are associated with RLS: one including common SNPs reported in[@R39],[@R40], and a second signal of low-frequency SNPs reported by[@R41],[@R42]. The Winkelmann RLS-associated SNPs in *MEIS1* are not genome-wide significant in our insomnia complaints GWAS, and are in low LD with our associated SNPs ([Supplementary Table 16](#SD1){ref-type="supplementary-material"}). Conditioning our top SNP rs113851554 on these SNPs ([Online Methods](#S13){ref-type="sec"}) showed that our top SNP has an effect (*P* = 2.90 × 10^-13^) independent from those RLS SNPs in *MEIS1*. We did not condition on the two SNPs of the second RLS signal in *MEIS1* (our top SNP rs113851554[@R42] and rs11693221[@R41]) as those SNPs were part of our top findings for insomnia complaints ([Table 1](#T1){ref-type="table"}).

Second, we applied BUHMBOX[@R45], which provides information on the likelihood that a heterogeneous RLS subgroup exists within our sample that could explain our association results ([Online Methods](#S13){ref-type="sec"}). After establishing sufficient power (0.82 reported by BUHMBOX power calculator based on sample size, RLS SNP effect sizes, and RLS prevalence, [Online Methods](#S13){ref-type="sec"}) to detect heterogeneity when defining RLS genetic structure by the six RLS-associated loci reported in the RLS GWAS[@R40] ([Supplementary Table 17](#SD1){ref-type="supplementary-material"}), we found no evidence that an RLS subgroup solely drives the reported associations, both when excluding the *MEIS1* locus (*P* = 0.33), and when including this locus (*P* = 0.36). However, adding our top SNP in *MEIS1* for insomnia complaints which was also previously associated with RLS[@R42] (*P* = 4.80 × 10^-12^), we did find excessive positive correlation for the RLS loci in a subgroup of the individuals reporting insomnia (*P* = 0.029), yet this was driven by this single SNP. Note that because of a lack of power (due to the small RLS sample size and smaller effect sizes of the insomnia loci), we could not test the reverse hypothesis that an insomnia subgroup drives the RLS associations.

Third, we performed a genetic risk score analysis ([Online Methods](#S13){ref-type="sec"}) to interpret the BUHMBOX results. This yielded a significant association between insomnia complaints and the RLS associated loci when including the same RLS loci as tested in BUHMBOX ([Supplementary Table 17](#SD1){ref-type="supplementary-material"}), namely; *i*) five RLS loci excluding the *MEIS1* locus (*P* = 7.28 × 10^-3^); *ii*) six RLS loci including the *MEIS1* association of the RLS GWAS (*P* = 6.23 × 10^-4^); and *iii*) six RLS loci including the *MEIS1* RLS-associated SNP that was the insomnia complaints top hit as well (*P* = 5.30 × 10^-13^). As in the BUHMBOX analysis, including the insomnia complaints top hit strongly increased the association. The results of the BUHMBOX and genetic risk score analyses together are compatible with pleiotropy, but phenotypic overlap between RLS and insomnia complaints might contribute to the association found in the *MEIS1* locus.

Fourth, we investigated possible confounding of RLS and insomnia at *MEIS1* using conditional phenotypic analysis in data of the Course of Restless Legs Syndrome study (COR; included in[@R40]) and the Dortmund Health Study (DHS), containing information on both RLS and insomnia complaints ([Online Methods](#S13){ref-type="sec"}, [Supplementary Note](#SD1){ref-type="supplementary-material"}). The combined COR+DHS sample included 1,985 individuals with quality-controlled genotypes ([Supplementary Table 18](#SD1){ref-type="supplementary-material"}). We note that this sample has strong ascertainment biases due to COR (53% of the combined sample) consisting only of patients who are relatively old (65 years on average) and, as members of RLS support groups, tend to have severe RLS. The resulting biases are *i*) oversampling of insomnia *evoked by* severe RLS because all individuals with insomnia complaints in COR necessarily have RLS, and *ii*) overrepresentation of RLS *comorbid with* insomnia because insomnia increases with age and people seeking help for RLS may be more likely to have comorbid insomnia. Keeping this in mind, *MEIS1* was found to be strongly associated with insomnia complaints, supporting our initial finding, and with RLS as expected ([Supplementary Tables 19 and 20](#SD1){ref-type="supplementary-material"}). Conditioning insomnia complaints on RLS and vice versa reduced the association signals, indicating that phenotypic overlap contributes to the associations of both phenotypes. However, this reduction, which was complete when conditioning insomnia complaints on RLS but incomplete when conditioning RLS on insomnia complaints, cannot exclude pleiotropy of *MEIS1* because of the strong ascertainment biases. Up to 83% of all insomnia cases in COR+DHS may belong to the subgroup that is evoked by severe RLS or comorbid with RLS ([Supplementary Table 18](#SD1){ref-type="supplementary-material"}), explaining why an effect of *MEIS1* on insomnia was not visible after conditioning on RLS.

Fifth, we predicted *P* values for insomnia complaints in the UK Biobank sample under the assumption that RLS alone drives the association. To this end we calculated the expected proportions of RLS individuals in the UK Biobank insomnia cases and controls, using data on age-specific RLS prevalence[@R46], on RLS sensitivity and specificity of the UK biobank question as derived from the NSR and Dortmund Health Study (DHS) sample, and on the reported rs113851554 effect size in RLS cases and controls[@R42] ([Supplementary Note](#SD1){ref-type="supplementary-material"}). A χ^2^ test resulted in a predicted association *P* value of 2 × 10^-4^ (95% CI 0.056-1.1 × 10^-11^; based on sampling variances; [Supplementary Note](#SD1){ref-type="supplementary-material"}). This predicted *P* value under the assumption that the complete signal was driven by an RLS subgroup was much weaker than the actual *P* value we observed (2.14 × 10^-18^), and the latter was outside of the 95% CI of the predicted *P* value. This finding thus supports the notion that the effect of *MEIS1* on insomnia complaints can at most be explained in part by an RLS contamination of the UK Biobank insomnia cases.

Finally, we conducted sign concordance and low *P* value enrichment tests ([Online Methods](#S13){ref-type="sec"}) on the summary statistics of insomnia complaints and RLS (unfortunately the sample of RLS GWAS[@R40] was insufficient to obtain a reliable estimate of genetic correlation). 78% of the independent top SNPs (*P* = 1 × 10^-4^) of insomnia complaints were sign-concordant in RLS, while 83% of the top SNPs of RLS were discordant ([Supplementary Table 21](#SD1){ref-type="supplementary-material"}). The top signals of both studies showed little overlap ([Supplementary Tables 22 and 23 and Supplementary Fig. 13](#SD1){ref-type="supplementary-material"}). This suggests that besides pleiotropy of some loci there are genetic factors specific to each of the two disorders.

Taken together, the above results suggest that phenotypic overlap between RLS and insomnia can drive some, but not all of the *MEIS1* insomnia association. This effect on the association likely has the same effect vice versa (i.e. insomnia complaints confounding RLS). Hence, we conclude that *MEIS1* is likely to have pleiotropic effects on both RLS and insomnia.

Overlap with sleep-related phenotypes {#S8}
-------------------------------------

Multiple sleep related phenotypes are present in the UK Biobank and multiple loci have been identified for sleep duration[@R24],[@R26], chronotype[@R25],[@R26], and excessive daytime sleepiness[@R24]. We performed GWASes on six additional sleep phenotypes in UK Biobank ([Supplementary Fig. 14, Supplementary Table 24](#SD1){ref-type="supplementary-material"}) and investigated the genetic and phenotypic correlations with insomnia complaints ([Supplementary Note](#SD1){ref-type="supplementary-material"}). Phenotypically, individuals reporting insomnia complaints have shorter sleep duration, have more trouble getting up, and have more unintentional dozing, but do not show a systematically different chronotype. Furthermore, insomnia complaints showed a significant positive genetic correlation with daytime dozing/sleeping (r~g~ = 0.51, *P* = 3.25 × 10^-4^) and napping during the day (r~g~ = 0.42, *P* = 3.95 × 10^-6^), and a negative genetic correlation with sleep duration (r~g~ = 0.47, *P* = 1.97 × 10^-16^; [Supplementary Table 25](#SD1){ref-type="supplementary-material"}). The loci identified for insomnia complaints showed no significant association with the six additional sleep phenotypes ([Supplementary Table 26](#SD1){ref-type="supplementary-material"}). In addition, we investigated possible confounding of other psychiatric, metabolic and social economic traits ([Online Methods](#S13){ref-type="sec"}, [Supplementary Note](#SD1){ref-type="supplementary-material"}). Adjustment of the significant SNP associations with insomnia complaints by these traits did not show confounding effects ([Supplementary Table 27](#SD1){ref-type="supplementary-material"}).

Sex-differences in genetic associations {#S9}
---------------------------------------

Females have a higher predisposition for insomnia[@R2] than males, which might result from sex-related differences in the genetic architecture. The genetic correlation between sexes was estimated at 0.79 (SE = 0.13) which was just significantly smaller than 1 (one-sided Wald test *P* = 0.045). This estimate is comparable to e.g. waist circumference for which between-sex genetic heterogeneity is expected, in contrast to height and BMI where no heterogeneity is found[@R47]. In keeping with these overall differences, the significant SNP- and gene-based association results also differed between the sexes except for *MEIS1* ([Fig. 2](#F2){ref-type="fig"}). Adding sex as an interaction term to the GWAS on the full sample ([Online Methods](#S13){ref-type="sec"}) did not result in genome-wide significant interactions ([Supplementary Fig. 15](#SD1){ref-type="supplementary-material"}), yet this may also be due to low statistical power for interaction analyses. Sign concordance and low *P* value enrichment tests of sex-specific results showed little evidence for overlap in the top signals ([Online methods](#S13){ref-type="sec"}, [Fig. 2](#F2){ref-type="fig"}, [Supplementary Tables 28-30](#SD1){ref-type="supplementary-material"}), suggesting that sex has a role in evoking specific genetic risk factors of insomnia. Whether X-chromosomal loci or sex-specific imprinting[@R48],[@R49] play a role, still needs to be determined. Our finding is in line with sex differences across most sleep variables[@R50], including subjective sleep complaints[@R51], the prevalence[@R2] and heritability[@R12] of insomnia, and physiological signatures of sleep both in the general population[@R52] and within the population that has insomnia[@R53].

Functional networks {#S10}
-------------------

We applied the heat diffusion algorithm HotNet2[@R54] ([Online Methods](#S13){ref-type="sec"}) to investigate protein-protein interaction networks enriched with genes most strongly related to insomnia complaints (*P* \< 0.1) in the full and sex-specific GWGASes ([Supplementary Note](#SD1){ref-type="supplementary-material"}, [Supplementary Table 31](#SD2){ref-type="supplementary-material"}, [Supplementary Figs. 16 and 17](#SD1){ref-type="supplementary-material"}). For each input gene, HotNet2 processes a heat diffusion algorithm on the protein-protein interaction network to define a local neighborhood of 'influence', followed by a two-stage multiple hypotheses test to identify recurrent subnetworks. As input for HotNet2, we selected genes with *P* \< 0.1 from the GWGAS, thereby considering crosstalk across pathways and network topology. In total, we observed twelve subnetworks of genes for males (*P* = 0.01, *δ* = 0.012, *k* = 7, expected = 8.24) and nine subnetworks for females (*P* = 0.02, *δ* = 0.014, *k* = 7, expected = 5.61; [Supplementary Fig. 18](#SD1){ref-type="supplementary-material"}). These subnetworks significantly overlapped with known pathways, mostly involved in transcription ([Online Methods](#S13){ref-type="sec"}, [Supplementary Table 32](#SD3){ref-type="supplementary-material"}). In females, one subnetwork involved *MEIS1* ([Fig. 3a](#F3){ref-type="fig"}) together with multiple homeobox genes, encoding a family of transcription factors important for development. Other subnetworks presented candidate genes at 'hotspots' that were not detected by GWGAS alone, among them *GNAS* in the largest of the subnetworks in females ([Fig. 3b](#F3){ref-type="fig"}). *GNAS* is an imprinted gene that is expressed from the maternal chromosome. It has metabolic functions and modulates REM and NREM sleep states[@R49]. This is especially interesting given that stronger maternal transmission[@R21], hypermetabolism[@R55] and instability of those sleep states[@R56] are all characteristic of insomnia. Future studies have to confirm the involvement of the identified subnetworks in insomnia.

Genetic overlap with other traits {#S11}
---------------------------------

Insomnia implies an increased risk for major health problems, notably in the domains of cardiovascular diseases[@R5]--[@R9], obesity[@R11], and psychiatric disorders like depression[@R4]. We assessed the genetic correlation of insomnia by whole-genome LD score regression[@R33] against 29 traits from these domains and additional anthropometric and life style traits ([Online Methods](#S13){ref-type="sec"}). Significant genetic correlations (conservatively adjusted for multiple testing: *P* \< 1.72 × 10^-3^ \[= 0.05/29\]) were observed between insomnia complaints and ten other traits ([Fig. 4](#F4){ref-type="fig"}, left panel; [Supplementary Table 33](#SD1){ref-type="supplementary-material"}). Strong positive genetic correlations were observed with anxiety (r~g~ = 0.59, *P* = 7.14 × 10^-5^), depressive symptoms (r~g~ = 0.53, *P* = 1.03 × 10^-17^), neuroticism (r~g~ = 0.44, *P* = 1.20 × 10^-25^), and Major Depressive Disorder (r~g~ = 0.41, *P* = 6.50 × 10^-4^). Other positive yet weaker genetic correlations were observed with metabolic traits, i.e. Type II Diabetes, waist circumference, waist-to-hip ratio, and body mass index. Strong but negative genetic correlations were observed with subjective well-being (r~g~ = -0.44, *P* = 5.64 × 10^-11^) and educational attainment (r~g~ = -0.34, *P* = 1.81 × 10^-22^). Of the 29 traits, 18 have also been assessed in the NSR, allowing to investigate the phenotypic differences of these phenotypes in insomnia cases versus controls. We found that the profile of the magnitudes (*d*) of phenotypic group differences ([Online Methods](#S13){ref-type="sec"}) was strikingly similar to the profile of genetic correlations (rank correlation 0.82; [Fig. 4](#F4){ref-type="fig"} right panel and [Supplementary Table 34](#SD1){ref-type="supplementary-material"}), providing further evidence for a link between the above mentioned traits and insomnia.

Discussion {#S12}
==========

We conducted a large scale GWAS and GWGAS on insomnia complaints, using a measure that reliably discriminates ID from non-affected controls. We identified five novel genes (*MEIS1*, *HHEX*, *RHCG*, *IPO7* and *TSNARE1*) and one locus (including *MEIS1*) that are associated with insomnia complaints and that were supported by joint analysis with an independent sample. These findings partly (i.e. two genes) overlapped with those reported in a recently published GWAS[@R24] using a slightly different operationalization of the phenotype, which was less discriminative of clinical ID cases versus controls. Our top association was with *MEIS1*, which was also found in[@R24], and has previously been implicated in RLS. Our extensive analyses now show that both residual phenotypic overlap and pleiotropy are relevant for the involvement of *MEIS1* in insomnia as well as RLS.

We also provided evidence of sex-specific genetic effects and showed genetic overlap with several psychiatric and metabolic disorders. These findings provide starting points for subsequent functional analyses to unravel the molecular neurobiological mechanisms underlying the vulnerability to ID.

Online Methods {#S13}
==============

UK Biobank sample {#S14}
-----------------

We used data provided by the UK Biobank Study[@R28] (see [URLs](#FN1){ref-type="fn"}). UK Biobank is a major national health resource including \>500,000 participants, with the aim of improving the prevention, diagnosis and treatment of a wide range of serious and life-threatening illnesses -- including cancer, heart diseases, stroke, diabetes, arthritis, osteoporosis, eye disorders, depression and forms of dementia. All participants provided written informed consent; the UK Biobank received ethical approval from the National Research Ethics Service Committee North West--Haydock (reference 11/NW/0382), and all study procedures were performed in accordance with the World Medical Association Declaration of Helsinki ethical principles for medical research. The current study was conducted under the UK Biobank application number 16406.

The study design of the UK Biobank has been described elsewhere[@R28],[@R57]. Briefly, in 2006-2010 about 9.2 million invitation letters to participate in the study were sent to all people aged 40-69 years who were registered with the National Health Service and living up to \~25 miles from one of the 22 study assessment centers. A total of 503,325 participants were recruited into the study[@R28]. Apart from registry based phenotypic information, extensive self-reported baseline data were collected by questionnaire, in addition to anthropometric assessments, and DNA collection. For the present study we focused on insomnia, which was measured as experiencing trouble falling asleep or waking up in the middle of the night ([Supplementary Note section 1.1](#SD1){ref-type="supplementary-material"}).

SNP analysis of the UK Biobank sample {#S15}
-------------------------------------

We used imputed genetic data from UK Biobank (May 2015 release) including \~73 million genetic variants in 152,249 individuals. Details on the data are provided elsewhere (see [URLs](#FN1){ref-type="fn"}). In summary, the first \~50,000 samples were genotyped on the UK BiLEVE custom array, and the remaining \~100,000 samples were genotypes on the UK Biobank Axiom array. After standard quality control of the SNPs and samples which was centrally performed by UK Biobank, the dataset comprised 641,018 autosomal SNPs in 152,256 samples for phasing and imputation. Imputation was performed with a reference panel that included the UK10K haplotype panel and the 1000 Genomes Project Phase 3 reference panel.

For the analyses in our study, we selected Caucasians only. After removal of related individuals, discordant sex, withdrawn consent, and missing phenotype data, 113,006 individuals remained for analysis ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}). This is the largest available GWAS sample for insomnia to date. Previous power analyses showed that a samples size of *n* = 40,000 already allows for high power (\>90%) detection of SNPs with small effect sizes explaining only 0.1% of the variance[@R58], indicating sufficient statistical power of detecting SNPs associated with insomnia in our sample.

Association tests were performed in SNPTEST[@R59] (see [URLs](#FN1){ref-type="fn"}), using a logistic regression including the covariates age, sex (for the full sample), genotyping array, and the top five genetically determined principal components and additional ones out of ten extra that were associated with the phenotype (tested by logistic regression). SNPs with imputation quality \<0.8 (based on the total sample, and on the Caucasians only) and MAF\<0.001 were excluded after the association analysis, resulting in 12,444,916 SNPs, 12,428,592 SNPs, and 12,432,937 SNPs for the full, male and female analyses respectively.

Gene analysis {#S16}
-------------

We used all 19,427 protein-coding genes from the NCBI 37.3 gene definitions as basis for a genome-wide gene-association study (GWGAS) in MAGMA[@R35] (see [URLs](#FN1){ref-type="fn"}). We annotated all SNPs of our association analysis to these genes, resulting in 18,355 genes that were covered by at least one SNP. We included a window around the genes of 2 kb before transcription start site and 1 kb after transcription stop site. Gene-association test were performed taking LD between SNPs into account. We applied a stringent Bonferroni correction to account for multiple testing.

A GWGAS can identify genes in which multiple genetic variants show a mild effect that is not sufficiently strong to be picked up by GWAS. On the other hand, while a GWAS analysis can indicate a significant locus including a gene, it is possible that this gene is not identified in the GWGAS because the genes can harbor many more SNPs that did not show an association signal, and the GWGAS takes all SNPs within the gene into account.

SNP analysis of the deCODE sample {#S17}
---------------------------------

The Icelandic GWAS dataset used in the current study is based on whole genome sequencing (WGS), chip genotyping and long range phasing of Icelandic population samples[@R60]. In brief, we whole genome sequenced 15,220 Icelanders using Illumina technology (Illumina, San Diego, CA, USA) to an average depth of at least 34X, resulting in the identification of some 94 million variants. Using imputation assisted by long-range haplotype phasing[@R61] and after removing variants with imputation information content below 0.8 as well as with an imputed minor allele frequency below 0.01%, we successfully inferred the genotypes of 32,463,443 variants in 434,571 Icelanders, of whom 151,677 had been genotyped using the Illumina chip genotyping platform. The remaining 282,894 Icelanders are first- and second degree relatives of the chip-typed individuals and are imputed by aid of genealogic information. Of the 3,774 cases and 3,791 controls used in this study, 3,671 and 3,697 were directly genotyped, respectively.

Logistic regression was used to test for associations between variants and insomnia, assuming a multiplicative model, treating disease status as the response and expected genotype counts from imputation as covariates. For the Icelandic cohort this was done using software developed at deCODE genetics[@R60]. Testing was performed using the likelihood ratio statistic and population stratification was adjusted for by including county of birth as covariates.

To account for inflation in test statistics due to cryptic relatedness and stratification within the case and control sample sets, we applied the method of LD score regression[@R33]. With a set of 1.1 million variants we regressed the χ2 statistics from our GWAS scan against LD score and used the intercept as a correction factor. The estimated correction factors were 1.059, 1.025 and 1.036 for the analysis including all, males only and females only, respectively. All *P* values were adjusted using these correction factors.

Genotyping and association analyses of the 'Course of Restless Legs Syndrome' and Dortmund Health Study samples {#S18}
---------------------------------------------------------------------------------------------------------------

1,051 Dortmund Health Study (DHS) participants were genotyped using the Illumina HumanOmni chip 2.5-4v1 and the GenomeStudio Genotype module. 1,057 'Course of Restless Legs Syndrome' (COR) study participants were genotyped using the Affymetrix Axiom CEU array and the Axiom GT1 algorithm. Genome-wide imputation of autosomal SNPs according to phase 3 of the 1000 Genomes Project was performed at the Sanger Imputation Service (see [URLs](#FN1){ref-type="fn"}). Quality control before imputation removed variants with genotyping rate of less than 95%, minor allele frequency of less than 10 × 10^-3^, or strong deviation from Hardy-Weinberg equilibrium (*P* \< 10 × 10^-8^), excluded individuals with sex-mismatch or genotyping rate of less than 95%, and finally selected a maximal set of unrelated individual (Pi hat \> 0.16). Variants were recoded before imputation according to human genome build 37 information on position, strand orientation, and major alleles, as reported by genotyping chip strand files (see [URLs](#FN1){ref-type="fn"}) and dbSNP (see [URLs](#FN1){ref-type="fn"}). Recoded datasets were merged by PLINK software[@R62] (see [URLs](#FN1){ref-type="fn"}) and subjected to multidimensional scaling (MDS) on 10 dimensions which involved outlier detection (\>4 SD from the population mean) and provided covariates besides age and sex for the association analyses. For the latter, the imputed genotypes were merged, yielding data on 1,985 individuals after quality control and outlier removal. For 1,772 of them, the three-level insomnia severity score was available. In case of individual SNPs, association analysis applied an additive model and linear or logistic regression as implemented in PLINK. For the gene analysis, MAGMA was used with the same phenotypes and covariates, using the same method in MAGMA as the GWGAS.

Credible set analysis {#S19}
---------------------

For the *MEIS1* locus, we defined a credible set of SNPs that could plausibly be considered as causal using PAINTOR (Probabilistic Annotation INTegratOR)[@R63]. PAINTOR uses a multivariate normal approximation to connect the LD structure of the SNPs in the locus to the *P* value. Data on functional annotation is integrated through an empirical Bayes prior, which results in a prior probability of a variant to be causal that is governed by its score on the functional classes. The SNPs scoring high on certain functional annotations are up-weighted, while the SNPs scoring low on a certain functional annotation are down-weighted. We included functional annotations reported in [Supplementary Note section 2.1](#SD1){ref-type="supplementary-material"} that contained information to prioritize the SNPs in the *MEIS1* locus: deleteriousness (continuous score), regulatory function (continuous score), meQTL (yes/no), and mean chromatin state over different tissues (continuous score).

Conditional analyses {#S20}
--------------------

We performed 2 types of conditional analyses for our SNPs associated with insomnia complaints: i) conditioning our top SNP rs113851554 in *MEIS1* upon three SNPs (rs6710341, rs12469063 and rs2300478) representing the association signals detected in RLS GWASes[@R39],[@R40]; ii) conditioning all SNPs significantly associated with insomnia complaints upon other traits and characteristics related to insomnia that were available in the UK Biobank study: waist-to-hip ratio, body mass index (BMI), Townsend deprivation index, years of education, depressive symptoms and neuroticism. Analyses were performed in SNPTEST[@R59] using the logistic regression model including covariates as described in the SNP analysis section. Additive effects of the SNPs in *i*) were added to the regression model with the -condition on flag. The phenotypes in *ii*) we added to the other covariates with the -cov_names flag.

Genotype × sex interaction analysis {#S21}
-----------------------------------

To investigate possible sex effects on insomnia complaints, we performed an association analysis adding sex as an interaction term in the original insomnia complaints GWAS using PLINK[@R62] (\--linear interaction). We analyzed the same SNPs included in the main GWAS of this study and included the same covariates (sex, age, array, principal components).

BUHMBOX {#S22}
-------

We applied Breaking Up Heterogeneous Mixture Based On Cross-locus correlations (BUHMBOX[@R45]; see [URLs](#FN1){ref-type="fn"}) to test if a heterogeneous subgroup that shows genetic characteristics of RLS is present in our UK Biobank insomnia sample, that should otherwise be homogeneous (i.e. is the sharing of risk alleles by insomnia and RLS driven by all individuals or a subset of individuals). We used the top SNPs of the six associated loci with RLS[@R40] with their risk alleles and allele frequencies ([Supplementary Table 17](#SD1){ref-type="supplementary-material"}) to define the genetic architecture of RLS. We first ran the BUHMBOX power calculator including 1000 simulations experiments including the UK Biobank sample size, risk allele frequencies and odds ratio's of the RLS SNPs ([Supplementary Table 17](#SD1){ref-type="supplementary-material"}), and proportion of expected RLS patients in the insomnia complaints group (0.107). BUHMBOX tests if the RLS risk alleles have higher allele frequencies only in a subset of insomnia cases (when pleiotropy would exist, the RLS risk alleles are expected to have higher allele frequencies across the total sample of insomnia cases). If the RLS risk alleles are enriched in one subgroup of insomnia cases, the expected correlations of number of risk alleles between the loci will be consistently positive. The pairwise correlations are combined in one statistic to test for excessive positive correlations.

Genetic risk score analysis {#S23}
---------------------------

We used the top SNPs of the six associated loci with RLS (same as for BUHMBOX) as input for the genetic risk score analysis. For each individual, we calculated the GRS by summing the risk allele dosage (0, 1 or 2) multiplied by the effect size (log\[OR\]) of the six top SNPs. An association analysis was performed between this genetic risk score and the UK Biobank insomnia phenotype using a logistic regression including the genetic principal components as covariates.

Sign concordance test {#S24}
---------------------

As input for the sign concordance test, we used independent SNPs that we defined by pruning the data with PLINK[@R62] (\--indep-pairwise 1000 100 0.1; see [URLs](#FN1){ref-type="fn"}). For the analysis with the RLS and insomnia complaints data, we first removed all SNPs with the allele combinations A/T and C/G to exclude strand ambiguity. In addition, all SNPs with non-matching alleles were removed. Sign concordance between two datasets was tested by a two-sided binominal test for a probability of 0.5, for SNP selections below six different *P* value thresholds (1, 0.5, 0.05, 1 × 10^-3^, 1 × 10^-4^, 1 × 10^-5^).

Low *P* value enrichment tests {#S25}
------------------------------

The pruned data used as input for the sign concordance test (see above) was used for the low *P* value enrichment test as well. Enrichment of low *P* values between two datasets was tested with a two-sided Fisher's exact tests on the cross tabs of the SNPs below and over four different *P* value thresholds (0.05, 1 × 10^-3^, 1 × 10^-4^, 1 × 10^-5^). In addition, because the RLS and insomnia complaints summary statistics are from samples that substantially differ in size (which is influencing the *P* values), we performed the analysis for seven different ranked *P* value thresholds as well (50, 100, 200, 400, 800, 1600, 3200).

Meta-analysis {#S26}
-------------

Meta-analysis of the SNPs in UK Biobank and deCODE was performed in METAL[@R64] (see [URLs](#FN1){ref-type="fn"}). The analysis was based on *P* values, taking sample size and direction of effect into account. Meta-analysis of the genes in UK Biobank and deCODE was performed in MAGMA[@R35] (see [URLs](#FN1){ref-type="fn"}), which uses the Stouffer's weighted Z-transform method.

HotNet2 analysis {#S27}
----------------

We applied the HotNet2 algorithm[@R54] to identify networks of genes that are related to insomnia. HotNet2 is based on a heat diffusion model. The key advantage of HotNet2 compared to conventional methods is the possibility to detect genes in connected subnetworks with associations to the phenotype stronger than expected by chance. Conventional gene enrichment or gene set analyses are limited by the rigid "in or out" definition of a gene set which does not allow for crosstalk between pathways that are represented by different gene sets. To depict an entire network topology, conventional enrichment tools therefore need to define a large number of gene sets resulting in a loss of statistical power due to a high level of multiple testing.

As input for the HotNet2 analysis we selected all genes from our GWGAS results with a *P* value ≤ 0.1 (2335, 2101, and 2077 genes for full, female, and male analyses respectively). The -log~10~(*P* value) was defined as input gene score. HotNet2 was performed based on protein-protein interactions reported by iRefIndex[@R65]. For four delta thresholds (minimum edge weight) that were automatically chosen by HotNet2, the significance of *N* subnetworks at *k* (the minimum number of proteins in a subnetwork) were reported based on a 100 times permuted influence matrix.

Next, we performed an enrichment analysis of the identified subnetworks by calculating a *P* value for the fraction of genes that overlaps with pre-defined pathways using the hypergeometric test. We selected all canonical pathways (*n* = 1,330) and Gene Ontology (GO) pathways (*n* = 1,454) from the molecular signature database (MSigDB v5.1[@R66], see [URLs](#FN1){ref-type="fn"}). A pathway was considered statistically significant when the hypergeometric test showed *P* ≤ 0.05 after correcting for multiple testing using the Benjamini and Hochberg method.

Genetic correlations {#S28}
--------------------

Genetic correlations (r~g~) were calculated between *i*) insomnia complaints and six other sleep related phenotypes present in UK Biobank; *ii*) insomnia complaints in males and females; *iii*) insomnia complaints and 29 other traits for which summary statistics from GWAS were publicly available ([Supplementary Table 33](#SD1){ref-type="supplementary-material"}), using LD score regression[@R33] (see [URLs](#FN1){ref-type="fn"}). We used pre-computed LD scores that were provided by LD score regression, which were calculated using the European panel of 1000 Genomes. No constraining of the intercept was applied. A conservative Bonferroni-corrected *P* value threshold of 1.72 × 10^-3^ was used in *iii* to define significant associations.

Phenotypic group differences between individuals with and without insomnia {#S29}
--------------------------------------------------------------------------

For 18 disorders, traits and characteristics measures in the Netherlands Sleep Registry (NSR)[@R29], group differences between 1,073 individuals without insomnia complaints and 845 likely to have ID were evaluated using t-tests (continuous phenotype) or χ^2^-tests (dichotomous phenotypes).
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![Manhattan plots for SNP associations with insomnia complaints.\
Association results for the frequency of experiencing trouble falling asleep or waking up in the middle of the night in 113,006 individuals of European descent in the UK Biobank study, of whom those experiencing these complaints usually (cases, *n* = 32,384) were contrasted with those experiencing these complaints never, rarely or sometimes only (controls, *n* = 80,622). (**a**) Manhattan plot of the GWAS including all individuals, (**b**) males only (12,863 cases and 40,776 controls), and (**c**) females only (19,521 cases and 39,846 controls). Negative log~10~-transformed *P* values for each SNP (y axis) are plotted by chromosomal position (x axis). The red and blue lines represent the thresholds for genome-wide statistical significant associations (*P* = 5 × 10^−8^) and suggestive associations (*P* = 1 × 10^−5^), respectively. Red dots represent top SNPs. (**d**) Manhattan plot of the gene analysis including all individuals, (**e**) males only, and (**f**) females only. Here, each dot represents a gene, and the red and blue lines represent the thresholds for gene-wide statistical significant associations (*P* = 2.72 × 10^−6^) and suggestive associations (*P* = 2.72 × 10^−5^), respectively.](emss-72665-f001){#F1}

![Comparison of association results for insomnia complaints in males and females.\
(**a**) SNP and (**b**) gene associations with insomnia complaints in males plotted against females. Contour lines indicate the density of the data in that region. The lines are colored from green to yellow, indicating increasing data density. Dotted lines indicate the *P* value thresholds used in the Low *P* value enrichment tests; from yellow to red *P* = 0.05, *P* \> 1 × 10^-3^, *P* = 1 × 10^-4^, and *P* = 1 × 10^-5^ (note that all SNPs present in both GWASes are displayed, while the enrichment tests were performed on pruned data).](emss-72665-f002){#F2}

![Protein-protein-interaction subnetworks identified by the heat diffusion algorithm HotNet2.\
The genes most strongly related to insomnia (*P* \< 0.1) in the full and sex-specific GWGASes were used as input to investigate the enrichment of protein-protein interaction networks. Each node (protein) is assigned a score based on the gene *P* value of the GWGAS. The scores, denoted as "heat" in HotNet2, diffuse across the edges of the network. We report subnetworks that include genes with a wide range of heat scores: red colored nodes send and receive a significant amount of heat, while blue colored nodes do not. (**a**) Subnetwork identified for females including *MEIS1*. (**b**) Subnetwork identified for females including *GNAS*. Other identified subnetworks for females and males are shown in [Supplementary Figure 18](#SD1){ref-type="supplementary-material"}.](emss-72665-f003){#F3}

![Genetic and phenotypic overlap between insomnia complaints and other traits and disorders.\
***Left bar chart:*** Genetic correlations (*r~g~*) between the frequency of experiencing trouble falling asleep or waking up in the middle of the night and various other traits and diseases. LD Score regression tested genome-wide SNP associations for these insomnia complaints against similar data for 29 other anthropometric and cardiovascular traits and neuropsychiatric outcomes ([Supplementary Table 33](#SD1){ref-type="supplementary-material"}). Error bars represent standard errors on these estimates. Red bars represent the traits that showed a significant genetic correlation after correction for multiple testing (*P* \< 1.72 × 10^−3^), pink bars the traits that showed nominal association (*P* \< 0.05), and blue bars the traits that did not show a significant genetic association. ***Right bar chart:*** The genetic correlations profile was strikingly similar to phenotypic overlap of insomnia with the same subject-characteristics assessed in an independent sample. Of the 29 disorders, traits and characteristics, 18 had been assessed in the NSR as well. Group differences between the 1,073 individuals without insomnia complaints and the 845 likely to have ID were evaluated using t-tests or χ^2^-tests ([Supplementary Table 34](#SD1){ref-type="supplementary-material"}). The profile of the magnitudes (*d*) of phenotypic group differences strongly resembled the genetic correlations profile.](emss-72665-f004){#F4}

###### Three genome-wide significant loci associated with insomnia complaints in a GWAS including 113,006 individuals and the sex-specific GWASes

                                                                                              FULL   MALE        FEMALE                                                                                                                                
  ------------- --------------------------------- --- ------------- ---- ---- ------- ------- ------ ----------- ------------------------------------------------ ------ ----------- ---------------------------------------------- ------ ----------- ------------------------------------------------
  rs375216017   *MEIS1* intron variant            2   66,728,627    GT   G    0.942   0.105   1.09   1.05-1.12   **1.21E-08**                                     1.09   1.04-1.14   2.27E-04                                       1.09   1.04-1.13   1.60E-05
  rs62144051    *MEIS1* intron variant            2   66,730,783    G    A    0.964   0.094   1.10   1.06-1.13   **3.81E-09[\*\*](#TFN4){ref-type="table-fn"}**   1.09   1.04-1.14   9.21E-04                                       1.10   1.06-1.15   1.01E-06
  rs62144053    *MEIS1* intron variant            2   66,745,864    A    G    0.964   0.095   1.10   1.06-1.13   **1.20E-09[\*\*](#TFN4){ref-type="table-fn"}**   1.08   1.03-1.13   1.79E-03                                       1.11   1.07-1.16   1.18E-07
  rs62144054    *MEIS1* intron variant            2   66,747,480    A    G    0.976   0.094   1.10   1.06-1.13   **1.68E-09[\*\*](#TFN4){ref-type="table-fn"}**   1.08   1.03-1.13   2.45E-03                                       1.11   1.07-1.16   1.09E-07
  rs113851554   *MEIS1* intron variant            2   66,750,564    T    G    1       0.056   1.19   1.14-1.24   **2.14E-18[\*\*](#TFN4){ref-type="table-fn"}**   1.18   1.11-1.25   1.69E-07                                       1.20   1.14-1.26   **2.25E-12[\*\*](#TFN4){ref-type="table-fn"}**
  rs182588061   *MEIS1* intron variant            2   66,757,709    T    G    0.852   0.020   1.21   1.13-1.28   **3.18E-10[\*](#TFN3){ref-type="table-fn"}**     1.21   1.10-1.33   7.08E-05                                       1.21   1.11-1.32   1.13E-06
  rs139775539   *MEIS1* intron variant            2   66,782,432    A    AC   0.961   0.048   1.19   1.14-1.24   **7.00E-17[\*](#TFN3){ref-type="table-fn"}**     1.17   1.09-1.24   2.49E-06                                       1.21   1.14-1.28   **4.08E-12[\*](#TFN3){ref-type="table-fn"}**
  rs11679120    *MEIS1* intron variant            2   66,785,180    A    G    0.960   0.047   1.19   1.14-1.24   **6.18E-17[\*](#TFN3){ref-type="table-fn"}**     1.18   1.11-1.26   5.54E-07                                       1.20   1.14-1.27   **2.09E-11[\*](#TFN3){ref-type="table-fn"}**
  rs115087496   *MEIS1* intron variant            2   66,793,725    C    G    0.950   0.047   1.18   1.13-1.23   **4.43E-15[\*](#TFN3){ref-type="table-fn"}**     1.16   1.09-1.24   7.00E-06                                       1.19   1.13-1.26   **9.91E-11[\*](#TFN3){ref-type="table-fn"}**
  rs549771308   *MEIS1* intron variant            2   66,795,237    C    CT   0.832   0.120   1.08   1.05-1.11   **9.51E-09[\*\*](#TFN4){ref-type="table-fn"}**   1.06   1.02-1.11   3.14E-03                                       1.09   1.05-1.13   5.17E-07
  rs11693221    *MEIS1* downstream gene variant   2   66,799,986    T    C    0.943   0.048   1.17   1.12-1.22   **3.79E-14[\*\*](#TFN4){ref-type="table-fn"}**   1.15   1.08-1.23   1.92E-05                                       1.19   1.12-1.25   **2.88E-10[\*\*](#TFN4){ref-type="table-fn"}**
                                                                                                                                                                                                                                                       
  rs574753165   *SCFD2* intron variant            4   53,977,261    G    A    0.930   0.005   1.40   1.24-1.57   **4.98E-09[\*](#TFN3){ref-type="table-fn"}**     1.38   1.15-1.65   1.85E-04                                       1.42   1.21-1.66   6.84E-06
                                                                                                                                                                                                                                                       
  rs71554396    intergenic                        6   169,841,072   GT   G    0.946   0.137   0.95   0.93-0.98   1.43E-03                                         0.89   0.85-0.93   **1.95E-08**                                   1.01   0.98-1.05   5.17E-01
  rs13208844    *WDR27* intron variant            6   169,961,603   G    A    1       0.147   0.96   0.93-0.98   1.50E-03                                         0.89   0.85-0.93   **2.25E-08[\*](#TFN3){ref-type="table-fn"}**   1.01   0.98-1.05   5.21E-01
  rs13192566    *WDR27* intron variant            6   169,961,635   C    G    0.999   0.146   0.95   0.93-0.98   1.26E-03                                         0.89   0.85-0.93   **1.80E-08[\*](#TFN3){ref-type="table-fn"}**   1.01   0.98-1.05   5.41E-01

Summary of the three significant loci present in the full GWAS and/or the male (*n* = 53,639) and female (*n* = 59,367) GWAS. All SNPs with *P* \< 5 × 10^-8^ in one of the analyses are reported for all three analyses. SNP *P* values and odds ratios were calculated for each GWAS with an additive genetic model using logistic regression adjusted for age, sex in the full GWAS, genotyping array, and principal components. Bold *P* values are significantly associated with insomnia (*P* \< 5 × 10^-8^). SNP association results in the deCODE sample and the meta-analysis are reported in [Supplementary Tables 11 and 13](#SD1){ref-type="supplementary-material"}. Chr, chromosome; BP, base pair; EA, effect allele; EAF. effect allele frequency; OR, odds ratio; CI, confidence interval.

reported on GRCh37.

Genome-wide significant in in the combined analysis of UK Biobank and deCODE.

Stronger association signal in the combined analysis of UK Biobank and deCODE.

###### Genome-wide significant genes associated with insomnia complaints in a GWGAS including 113,006 individuals and the sex-specific GWGASes

                                                        FULL   MALE       FEMALE                                                                                                                           
  ----------- -------- ---- ------------- ------------- ------ ---------- ---------------------------------------------- ------ ---------- --------------------------------------------- ------ ---------- ---------------------------------------------
  *DCBLD1*    285761   6    117,801,803   117,892,021   384    4.54E-07   **0.0083**                                     385    0.0856     1                                             386    7.12E-06   0.131
  *MEIS1*     4211     2    66,660,257    66,800,891    426    6.60E-07   **0.0121[\*\*](#TFN8){ref-type="table-fn"}**   424    7.56E-03   1                                             428    3.58E-04   1
  *MED27*     9442     9    134,734,497   134,957,274   608    7.81E-07   **0.0143[\*](#TFN7){ref-type="table-fn"}**     608    9.56E-03   1                                             603    5.41E-04   1
                                                                                                                                                                                                           
  *HHEX*      3087     10   94,447,681    94,456,408    19     2.49E-03   1                                              19     1.71E-06   **0.031[\*\*](#TFN8){ref-type="table-fn"}**   19     0.5832     1
  *RHCG*      51458    15   90,013,638    90,041,799    35     1.15E-04   1                                              34     2.19E-06   **0.040[\*\*](#TFN8){ref-type="table-fn"}**   35     0.7115     1
                                                                                                                                                                                                           
  *IPO7*      10527    11   9,404,169     9,470,674     241    7.80E-04   1                                              234    0.7839     1                                             245    1.67E-06   **0.031[\*\*](#TFN8){ref-type="table-fn"}**
  *TSNARE1*   203062   8    143,292,441   143,486,543   1083   0.029503   1                                              1074   0.9498     1                                             1079   1.76E-06   **0.032[\*\*](#TFN8){ref-type="table-fn"}**

Gene-based *P* values are reported for all genes significant after Bonferroni correction (α = 2.72E-06) in at least one of the three analyses (full, males, females). Bold *P* values are significantly associated with insomnia. Gene association results in the deCODE sample and the meta-analysis are reported in [Supplementary Tables 12 and 14](#SD1){ref-type="supplementary-material"}. GWGAS, genome-wide gene-association study; Chr, chromosome; BP, base pair; *P* corr, *P* corrected for multiple testing.

reported on GRCh37, Including a window of 2,1 kb.

Genome-wide significant in in the combined analysis of UK Biobank and deCODE.

Stronger association signal in the combined analysis of UK Biobank and deCODE.
